About this event
Since the emergence of the novel coronavirus SARS-CoV-2 in December 2019, over 115 million cases have been reported worldwide. Whole genome sequencing and global genomic data sharing is playing a pivotal role in the response to the Coronavirus pandemic.
Join us for COVID & Genomics ONLINE, a 4-part webinar series that will share the very latest research and insights from leading experts covering key aspects of the pandemic; from mechanisms of cell entry and disease severity, through to how genomics data is shaping our response to the pandemic.
From this series you will hear detailed, end-to-end analysis of the role of genomics in different aspects of tackling the COVID-19 pandemic, as well as the lessons learned from some of the leading experts in the fight against SARS-CoV-2.
Genomic surveillance has shaped our understanding of SARS-CoV-2. Comparative analysis with SARS-CoV has indicated that the two viruses use the same receptor binding domain, known as the ACE 2 receptor.
This webinar will focus on global research that has evaluated the SARS-CoV-2 genome to understand the mechanisms of entry into host cells. We will also discuss how global data sharing has enabled us to identify variations in genes that could explain the differences seen between severity of infections in patients, which could facilitate better management of the disease in the future.
SARS-CoV-2 entry routes to the central nervous system in COVID-19
Pathophysiology of COVID-19: mechanisms underlying disease severity and progression
Genetic variants that are associated with risk of COVID-19 related mortality
SARS-CoV-2 is a large RNA virus with potential for genetic recombination, point mutation and limited replication error correction. Routine analysis of genetic sequence data enables researchers and public health bodies to identify and characterise variant viruses.
This webinar will focus on global research that interrogates the coronavirus genome to recognise and characterise emerging novel variants of the virus and their impact on transmission, susceptibility to treatments and whether our existing testing methods will be effective in the future.
Scaling up SARS-CoV-2 genomic analyses to facilitate global surveillance of variants of concern
The importance of hybrid-capture technology to recognise and characterize emerging novel variants
Wastewater-based monitoring of SARS-CoV-2 infections in small and large populations
This webinar will focus on how SARS-CoV-2 genome sequencing data has enabled identification of vaccine targets for COVID-19, and whether AI drug discovery screening will uncover drug repurposing candidates for the development of future treatments. We will also discuss the importance of producing a low-cost scalable vaccine for global health.
COVID-19 asymptomatic infections, the NIH national serosurvey phase I results and what they tell us about risk factors and vaccines
Flexibility and mobility of possible SARS-CoV-2 drug targets
Single cell genomics: insights into COVID immunology
Structural design and genetic engineering of yeast-expressed recombinant SARS-CoV-2 proteins as COVID-19 vaccine candidates
Traditionally, vaccine development has taken many years. The urgent need for COVID-19 vaccines and unprecedented global cooperation and data sharing has facilitated the development of vaccines in under a year.
We will discuss how researchers across the globe mobilized to share COVID genomic data, and whether the coronavirus pandemic has changed our perceptions of data sharing moving forward.
Changing the perception of data sharing in Canada: from superfluous commodity to strategic priority
Prioritising SARS-CoV-2 mutations and variants
Data sharing in a time of pandemic
Front Line Genomics is a genomics-focused media company, with a social mission to deliver the benefits of genomics to patients faster. We organise the Festival of Genomics, digital events and webinars. We also produce reports and operate a content-rich website.